Sustainable chemotherapy schedules

Mostrar todas las versiones(2)

We used a discrete time version of viabilitytheory in order to study the sustainable therapies againstthe cancer. We assume that the tumor is composed of twosubpopulations, one resistant and the another sensitive. Weconsider a discrete model in order to simulate the responseof this tumor to therapy,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barrea, Andrés Alberto, Hernández, Matias Ezequiel
Formato:	conferenceObject submittedVersion
Lenguaje:	Inglés
Publicado:	2021
Materias:	Chemotherapy Cancer Bellman Tumor Viability
Acceso en línea:	http://hdl.handle.net/11086/22070
Aporte de:	Repositorio Digital Universitario (UNC) de Universidad Nacional de Córdoba

Ejemplares similares

Sustainable chemotherapy schedules
por: Barrea, Andrés Alberto, et al.
Publicado: (2021)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018)

The chemotherapy source book /
Publicado: (2008)

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018)

Cancer chemotherapy and biotherapy : principles and practice /
Publicado: (2006)

Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field
por: Rico, María José, et al.
Publicado: (2018)

Targeted therapy in translational cancer research /
Publicado: (2016)

Manual de quimioterapia del cáncer /
Publicado: (2012)

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012)

Handbook of targeted cancer therapy /
Publicado: (2015)

Pharmacogenetics of breast cancer : towards the individualization of therapy /
Publicado: (2008)

Controlador óptimo con observación de estados basados en el principio del máximo de Pontryagin de bajo costo conceptual
por: Herrera, Martín, et al.
Publicado: (2025)

Manual de quimioterapia del c�ancer /
Publicado: (2012)

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018)

Quimioterapia antineoplásica en pacientes internados
por: Boquete, Alejandra L.
Publicado: (1993)

The understanding of information about oral chemotherapy treatment among outpatients at a University Hospital in Ceará, Brazil
por: Pereira, Ana G. da S., et al.
Publicado: (2010)

Optimal dividend strategies for a catastrophe insurer
por: Albrecher, Hansjörg, et al.
Publicado: (2023)

Ecancermedicalscience

Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Expresi�on inmunohistoqu�imica de la prote�ina de multirresistencia a drogas (gp-170) en biopsias de tejido mamario humano normal y tumoral /
por: Villasmil Colina, �Angel R.
Publicado: (2012)

Chemotherapy :

A Symmetrical Dirhenium(I) Complex with 4,4’’-Azobis(2,2’-bipyridine) as a Bridging Ligand: Synthesis, Physicochemical Properties and Applications in Detection of Biologically Relevant Thiols and in Chemotherapy for Bone Cancer
por: Abate, Pedro Oscar, et al.
Publicado: (2020)

Pharmacotherapeutics for advanced practice : a practical approach /
Publicado: (2013)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2018)

Essential cancer pharmacology : the prescriber's guide /
por: Butler, Sara K.
Publicado: (2011)

Achievements and challenges in the use of metronomics for the treatment of breast cancer
por: Scharovsky, O. Graciela, et al.
Publicado: (2020)

Rol de la inflamación sistémica en la patología generada por tumores murinos
por: Bruzzo Iraola, Juan
Publicado: (2014)

Rol de la inflamación sistémica en la patología generada por tumores murinos
por: Bruzzo Iraola, Juan
Publicado: (2013)

Rol de la inflamación sistémica en la patología generada por tumores murinos
por: Bruzzo Iraola, Juan
Publicado: (2014)

False hope bone marrow transplantation for breast cancer /
Publicado: (2007)

Neoadjuvant breast cancer: statistical and histopathological analysis of tumor response. Casuistry of the National Hospital of Clinics
por: Anglada , GA, et al.
Publicado: (2023)

Biolog�ia tumoral, claves celulares y moleculares del c�ancer
por: Bal de Kier Joff�e, Elisa
Publicado: (2008)

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
por: Blajman, C., et al.

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
Publicado: (1999)

Nuevos blancos para tratar el cáncer.
por: Valette, Annie

Radiobiological research and radiotherapy : proceedings of an International Symposium on the Radiobiological Research Needed for the Improvement of Radiotherapy held by the International Atomic Energy Agency in Vienna, 22-26 November 1976.
Publicado: (1977)

Las semillas del cáncer.
por: Coluccio Leskow, Federico

Charge density as a molecular descriptor to reveal differences on high active cruzain inhibitors
por: Luchi, Adriano Martín, et al.
Publicado: (2025)

Optimal dividend strategies for a catastrophe insurer
por: Azcue, Pablo, et al.
Publicado: (2024)